Terrestrial gamma radiation dose rate in Cienfuegos, Cuba

This study assesses the level of background radiation for Cienfuegos Province, Cuba. Measurements of outdoor gamma radiation (of terrestrial and cosmic origin) in air were performed at 198 locations using a GPS navigator and a dose meter (SRP-68-01, 30 × 25 mm NaI detector). The average absorbed dose was found to be 73.9 nGy h-1 (17.2–293.9 nGy h-1), corresponding to an annual effective dose of 74.7 μSv (21–324 μSv). When compared with the data available for other places, the absorbed gamma doses obtained in this study indicate a background radiation level that falls within natural limits for the Damuji, Salado and Caonao watersheds; however, the Arimao and Gavilanes watersheds present levels of the absorbed dose and annual effective dose comparable with high background radiation areas. An isodose map of the terrestrial gamma dose rate in Cienfuegos was drawn using the GIS application “Arc View”. This study provides important baseline data of radiation exposure in the area

Management of cerebral venous thrombosis in Spain : MOTIVATE descriptive study Manejo de la trombosis venosa cerebral en España: estudio descriptivo MOTIVATE

Introduction: Cerebral venous thrombosis (CVT) is an uncommon cause of stroke that mainly affects young adults. Early, accurate diagnosis can reduce the rate and severity of complications. Objective: The aim of this study was to analyse the clinical characteristics, management, and treatment of CVT in different centres in Spain. Methods: We conducted a multicentre, retrospective, descriptive study of patients hospitalised due to CVT between 2008 and 2017 at 11 Spanish centres. Results: We included 256 patients, with a mean age (SD) of 49.8 (18.7) years; 51% of patients were women. The most frequent symptoms were headache (73%), focal deficits (50%), epileptic seizures (33%), and encephalopathy (21%). The most frequent localisations were the superior sagittal sinus (12.5%), the transverse sinus (10.9%), and 2 or more sinuses or veins (66.4%). Thrombophilia was the most frequent known aetiology (24%), and was most commonly associated with the prothrombin G20210A mutation (19%). Forty-six percent of patients were treated with antithrombotics for 3-6 months, 21% for one year, and 22.6% required indefinite anticoagulation. Endovascular therapy was performed in 5% of cases, and 33% required neurosurgery. Regarding outcomes, 75% of patients were independent at 3 months (modified Rankin Scale [mRS] score ≤ 2), with papilloedema (P =.03), focal deficits (P =.001), and encephalopathy (P 3). The in-hospital mortality rate was 4.3%, with a 3-month mortality rate of 6.3%. Conclusion: The diverse risk factors and variable presentation of CVT represent a challenge in the diagnosis and treatment of this condition. To improve prognosis and reduce mortality, it is essential to establish management protocols for this entity